Entrada Therapeutics, Inc.
TRDA
$11.88
-$0.71-5.64%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -19.52% | -17.23% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -19.52% | -17.23% | |||
| Cost of Revenue | -15.91% | 1.28% | |||
| Gross Profit | 15.75% | -2.28% | |||
| SG&A Expenses | -9.26% | -5.66% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -14.50% | -0.27% | |||
| Operating Income | 14.33% | -0.43% | |||
| Income Before Tax | 10.14% | -1.29% | |||
| Income Tax Expenses | -85.93% | 267.42% | |||
| Earnings from Continuing Operations | 11.26% | -2.39% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 11.26% | -2.39% | |||
| EBIT | 14.33% | -0.43% | |||
| EBITDA | 13.97% | -0.01% | |||
| EPS Basic | 11.56% | -2.08% | |||
| Normalized Basic EPS | 14.80% | -0.99% | |||
| EPS Diluted | 11.56% | -2.08% | |||
| Normalized Diluted EPS | 14.80% | -0.99% | |||
| Average Basic Shares Outstanding | 0.34% | 0.30% | |||
| Average Diluted Shares Outstanding | 0.34% | 0.30% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||